Gianluca Del Conte

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

Matt D. Galsky, Gianluca Del Conte, Silvia Foti et al. · Journal of Clinical Oncology · 2022 · 85 citations

Immunology, Immunoediting, Pathology +17

Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study

Erika Hamilton, Charles L. Shapiro, Daniel P. Petrylak et al. · Cancer Research · 2021 · 53 citations

Breast Oncology, Immunology, Pathology +18

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Erika Hamilton, Matthew D. Galsky, Sebastian Ochsenreither et al. · Clinical Cancer Research · 2024 · 31 citations · Full text

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial

Gilberto Filaci, Daniela Fenoglio, Franco Nolè et al. · Cancer Immunology Immunotherapy · 2021 · 30 citations · Full text

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Víctor Moreno, David Olmos, Carlos Gomez‐Roca et al. · Clinical Cancer Research · 2014 · 19 citations